Leadership Shift in European Pharma: Kai Beckmann Leads Merck KGaA as Belén Garijo Joins Sanofi

Kai Beckmann has officially assumed the role of Chief Executive Officer at Merck KGaA, marking a new chapter for the German science and technology leader. The transition occurs as former CEO Belén Garijo departs the company to lead French rival Sanofi SA. Garijo's departure follows a 15-year tenure at Merck KGaA, where she spent six years leading the Healthcare division and served as the company's CEO since 2021. Notably, Garijo made history as the first woman to lead a company listed on Germany's DAX40 index. Beckmann is a long-time veteran of Merck KGaA, having joined the organization in 1989. He has been a member of the Executive Board since 2011 and previously managed the Performance Materials business sector starting in 2017. He had been serving as the CEO of the Electronics division and Deputy Chair of the Executive Board prior to his full appointment. At Sanofi, Garijo succeeds Paul Hudson, whose tenure ended on February 17. Following a brief interim period led by Olivier Charmeil, Garijo officially took charge following the Group's Annual General Meeting on April 29. Sanofi expects Garijo to accelerate the implementation of its corporate strategy and prepare the firm for future growth. These leadership changes represent a strategic reshuffling among Europe's top pharmaceutical and chemical players. While the transitions were planned, the market will monitor how Beckmann's electronics background influences Merck's direction and how Garijo's track record translates to Sanofi's operational rigor.